Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

In this case study, donor lymphocyte infusions effectively eradicated measurable residual disease in a patient with relapsed acute myeloid leukemia after hematopoietic cell transplantation, while side effects included the development of vitiligo and alopecia areata, likely due to chronic graft-versus-host disease.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

In this study, a newly engineered scaffold, PADM-MX-Ag-Si@Dox, demonstrated potential as a multifunctional biomaterial for postoperative melanoma treatment by controlling drug release, enhancing wound healing, and enabling real-time tumor surveillance through temperature, pH, and electrical stimuli.

This study found that theabrownin-selenium nanoparticles (TB-Se NPs) effectively target Malassezia-induced dermatitis through a dual antifungal and immunomodulatory mechanism, suppressing fungal overgrowth, reducing inflammation, and enhancing immune memory to prevent recurrence in a dermatitis model.

This case report describes a 79-year-old woman who developed alopecia universalis shortly after recovering from COVID-19, highlighting its relapsing nature and the challenges in long-term disease management.

This review discusses teriflunomide as a disease-modifying therapy for multiple sclerosis and highlights its effectiveness and safety in clinical trials, but reports no new clinical results.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

In this prospective cohort study, 62.5% of alopecia areata patients achieved significant hair regrowth by week 24, but 31.8% experienced relapses by week 52, with baseline severity and disease activity influencing outcomes and quality of life improving significantly over the study period.

This article discusses the evaluation of minimal residual disease in childhood acute lymphoblastic leukemia using molecular methods and reports no new findings.

This study concluded that teriflunomide has a consistent and manageable safety profile, with common mild-to-moderate adverse events and no new safety concerns identified over up to 12 years of treatment.

This study found that PUVA treatment resulted in complete hair regrowth in over half of patients with alopecia areata totalis or universalis, despite a higher treatment failure rate in those with a family history of the condition.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This study found that systemic corticosteroids led to satisfactory hair regrowth in 38.9% of severe alopecia areata patients, but hair fall occurred upon therapy discontinuation or tapering.

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

This article is a letter to the editor about high-dose pulsed corticosteroid therapy combined with methotrexate for severe childhood alopecia areata and provides no new clinical results.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

This article addresses erosive pustular dermatosis of the scalp, particularly in Australia's elderly population, and proposes a management plan to improve their quality of life, without presenting new clinical results.

In this study, late-onset alopecia areata in Israeli patients was predominantly observed in females with mild disease, showing a high rate of complete hair regrowth but frequent relapses.

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.

This study found that while no predictive factors for response to vismodegib were identified, longer treatment duration was associated with a lower risk of relapse in basal cell carcinoma patients.

This study observed that alopecia areata in children often presents as mild scalp patches, with the majority showing some hair regrowth following treatment, particularly when using potent topical steroids, which were most commonly prescribed in the reviewed cases.

This article discusses the perspectives of clinicians and patients on alopecia areata, an autoimmune disorder with significant psychosocial impacts, highlighting the unpredictability and limited effectiveness of current treatments as well as the key unmet needs and gaps in care.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This study examined Chinese adult patients' discussions on social media about JAK inhibitors for alopecia areata, highlighting significant interest in these treatments but also concerns about efficacy, relapse, side effects, and the emotional impact of the condition.

In this study, frontal fibrosing alopecia showed a higher cumulative remission rate compared to lichen planopilaris, despite similar timeframes and relapse rates between the two conditions.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.